Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:

 H.C. Wainwright 3rd Annual NASH Investor Conference
 Date:
Time:
Speaker:
Location:
Webcast:
Monday, October 21
11:20am ET
M. Scott Harris M.D., Chief Medical Officer
St. Regis Hotel, New York City
https://ir.altimmune.com/investors/events-and-presentations
   
 BIO Investor Forum
 Date:
Time:
Speaker:
Location:
Webcast:
Wednesday, October 23
12:45pm ET/9:45am PT
Vipin K. Garg Ph. D., President and Chief Executive Officer
Westin St. Francis Hotel, San Francisco, CA
https://ir.altimmune.com/investors/events-and-presentations
   
 Jefferies 2019 London Healthcare Conference
 Date:
Attendees:
   
Location:
November 20 and November 21 (one-on-one meetings only)
Vipin K. Garg Ph.D., President and Chief Executive Officer
Will Brown, Chief Financial Officer
Waldorf Hilton, London, UK

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company’s diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShieldTM and NasoVAXTM). For more information on Altimmune, please visit www.altimmune.com.

Contacts 
Will BrownAshley R. Robinson
Chief Financial OfficerManaging Director LifeSci Advisors
Phone: 240-654-1450Phone: 617-535-7742
Email: wbrown@altimmune.comEmail: arr@lifesciadvisors.com

 

Primary Logo





×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.